메뉴 건너뛰기




Volumn 20, Issue 5, 2013, Pages 478-483

Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients

Author keywords

Metastatic renal cell carcinoma; Renal cancer medical treatment; Sunitinib; Treatment toxicity; Tyrosine kinase inhibitors

Indexed keywords

SUNITINIB;

EID: 84877339187     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03204.x     Document Type: Article
Times cited : (50)

References (25)
  • 1
    • 3042820411 scopus 로고    scopus 로고
    • Renal cell carcinoma
    • Curti B. Renal cell carcinoma. JAMA 2004; 292: 97-100.
    • (2004) JAMA , vol.292 , pp. 97-100
    • Curti, B.1
  • 3
    • 0033978220 scopus 로고    scopus 로고
    • Systemic therapy for renal cell carcinoma
    • Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 2000; 163: 408-417.
    • (2000) J. Urol. , vol.163 , pp. 408-417
    • Motzer, R.J.1    Russo, P.2
  • 4
    • 0027192081 scopus 로고
    • Immunotherapy for metastatic renal cell carcinoma
    • Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol. Clin. North Am. 1993; 20: 283-295.
    • (1993) Urol. Clin. North Am. , vol.20 , pp. 283-295
    • Wirth, M.P.1
  • 5
    • 0029090362 scopus 로고    scopus 로고
    • Phase III randomized trial of interleukin-2 with or without linphokine-activated killer sense in the treatment of patients with advanced renal cell carcinoma
    • Law TM, Motzer RJ, Mazumdar M etal. Phase III randomized trial of interleukin-2 with or without linphokine-activated killer sense in the treatment of patients with advanced renal cell carcinoma. Cancer 1996; 76: 824-832.
    • (1996) Cancer , vol.76 , pp. 824-832
    • Law, T.M.1    Motzer, R.J.2    Mazumdar, M.3
  • 6
    • 0027199879 scopus 로고
    • Subcutaneous interleukin-2 plus interferon-α- in metastatic renal cancer
    • Vogelzang NJ, Lipton A, Figlin RA etal. Subcutaneous interleukin-2 plus interferon-α- in metastatic renal cancer. J. Clin. Oncol. 1993; 11: 1809-1816.
    • (1993) J. Clin. Oncol. , vol.11 , pp. 1809-1816
    • Vogelzang, N.J.1    Lipton, A.2    Figlin, R.A.3
  • 7
    • 0033056820 scopus 로고    scopus 로고
    • Citokines in metastatic renal cell carcinoma
    • Escudier B, Chevreau C, Lasset C etal. Citokines in metastatic renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2039-2043.
    • (1999) J. Clin. Oncol. , vol.17 , pp. 2039-2043
    • Escudier, B.1    Chevreau, C.2    Lasset, C.3
  • 8
    • 0035835819 scopus 로고    scopus 로고
    • The von Hippel-Lindau tumor suppressor gene
    • Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell Press 2001; 264: 117-125.
    • (2001) Exp. Cell Press , vol.264 , pp. 117-125
    • Kondo, K.1    Kaelin Jr., W.G.2
  • 9
    • 18344396226 scopus 로고    scopus 로고
    • Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma
    • Kondo K, Yao M, Yoshida M etal. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma. Genes Chromosomes Cancer 2002; 34: 58-68.
    • (2002) Genes Chromosomes Cancer , vol.34 , pp. 58-68
    • Kondo, K.1    Yao, M.2    Yoshida, M.3
  • 10
    • 0037307858 scopus 로고    scopus 로고
    • The von Hippel-Lindau tumor suppression protein: new insights into oxygen sensing and cancer
    • Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppression protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 2003; 13: 55-60.
    • (2003) Curr. Opin. Genet. Dev. , vol.13 , pp. 55-60
    • Kim, W.1    Kaelin Jr., W.G.2
  • 11
    • 78650874372 scopus 로고    scopus 로고
    • Sunitinib inhibits KIN and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. Sunitinib inhibits KIN and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003; 2: 471-478.
    • (2003) Mol. Cancer Ther. , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3    Pryer, N.K.4    Cherrington, J.M.5
  • 12
    • 0038204144 scopus 로고    scopus 로고
    • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    • O'Farrel AM, Abrams TJ, Yuen HA etal. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
    • (2003) Blood , vol.101 , pp. 3597-3605
    • O'Farrel, A.M.1    Abrams, T.J.2    Yuen, H.A.3
  • 13
    • 0345359585 scopus 로고    scopus 로고
    • An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
    • O'Farrel AM, Foran JM, Fiedler W etal. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 2003; 9: 5465-5476.
    • (2003) Clin. Cancer Res. , vol.9 , pp. 5465-5476
    • O'Farrel, A.M.1    Foran, J.M.2    Fiedler, W.3
  • 14
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors
    • Mendel DB, Laird AD, Xin X etal. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin. Cancer Res. 2003; 9: 327-337.
    • (2003) Clin. Cancer Res. , vol.9 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3
  • 15
    • 37249072373 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1 week off period
    • Britten CD, Kabbinavar F, Hecht JR etal. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1 week off period. Cancer Chemoter Pharmacol. 2008; 61: 515-524.
    • (2008) Cancer Chemoter Pharmacol. , vol.61 , pp. 515-524
    • Britten, C.D.1    Kabbinavar, F.2    Hecht, J.R.3
  • 16
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Ins. 2000; 92: 205-216.
    • (2000) J. Natl. Cancer Ins. , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 17
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989; 10: 1-10.
    • (1989) Control. Clin. Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 18
    • 33845382806 scopus 로고
    • Non-parametric estimation from incomplete observation
    • Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc. 1958; 53: 457-481.
    • (1958) J. Am. Stat. Assoc. , vol.53 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 19
    • 84877348319 scopus 로고
    • Extract confidence limits
    • Geigy scientific tables
    • Lentner C. Extract confidence limits. Geigy scientific tables 1982;89-102.
    • (1982) , pp. 89-102
    • Lentner, C.1
  • 20
    • 1442290393 scopus 로고    scopus 로고
    • Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
    • Motzer RJ, Bacik J, Schwartz LH etal. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2004; 22: 454-463.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 454-463
    • Motzer, R.J.1    Bacik, J.2    Schwartz, L.H.3
  • 21
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Brian I, Ronald M etal. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
    • (2006) JAMA , vol.295 , pp. 2516-2524
    • Motzer, R.J.1    Brian, I.2    Ronald, M.3
  • 22
    • 2442669093 scopus 로고    scopus 로고
    • Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
    • Abrams TJ, Murray LJ, Pesenti E etal. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003; 2: 1011-1021.
    • (2003) Mol. Cancer Ther. , vol.2 , pp. 1011-1021
    • Abrams, T.J.1    Murray, L.J.2    Pesenti, E.3
  • 23
    • 19944431093 scopus 로고    scopus 로고
    • A phase I study of SU 11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease
    • Fielder W, Seve H, Dohner H etal. A phase I study of SU 11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease. Blood 2005; 105: 986-993.
    • (2005) Blood , vol.105 , pp. 986-993
    • Fielder, W.1    Seve, H.2    Dohner, H.3
  • 24
    • 70249084594 scopus 로고    scopus 로고
    • Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
    • Escudier B, Roigas J, Gillssen S etal. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 4068-4075.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 4068-4075
    • Escudier, B.1    Roigas, J.2    Gillssen, S.3
  • 25
    • 84863116418 scopus 로고    scopus 로고
    • Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
    • Barrios CH, Hernandez-Barajas D, Brown MP etal. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012; 118: 1252-1259.
    • (2012) Cancer , vol.118 , pp. 1252-1259
    • Barrios, C.H.1    Hernandez-Barajas, D.2    Brown, M.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.